Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Basilea Licenses A Drug After Setback

by Ann M. Thayer
March 1, 2010 | A version of this story appeared in Volume 88, Issue 9

Basilea Pharmaceutica has licensed its antifungal agent isavuconazole, now in Phase III studies, to Japan’s Astellas Pharma. The Swiss firm will receive about $70 million up front and as much as $440 million in milestone payments. The partners will jointly develop the drug, and Astellas will cover commercialization costs. Separately, Basilea is regaining rights to the antibiotic ceftobiprole, licensed in 2005 to the Johnson & Johnson company Cilag. U.S. and European regulators rejected applications for the drug’s approval, questioning the reliability of data from J&J-run trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.